How clinicians can turn everyday observations into publishable research: spotting the gap, choosing the right paper type, and ...
The professor of neurology at the University of Michigan Medical School discussed the themes that defined SLEEP 2026, and what they signal for clinical practice heading into 2027. [WATCH TIME: 5 ...
Brain insulin resistance serves as the current thematic focus, reinforcing emerging metabolic-neurologic intersections ...
Welcome to NeurologyLive® 's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive 's widespread coverage in ...
Neurologists Robert Bermel, MD; Rebecca Cebull, CNP; and Marisa McGinley, DO, discuss where serum neurofilament light and ...
The FDA was busy in September 2026, issuing a number of decisions on potential new therapies, including approvals, clearances ...
Overall, fluctuating symptom control was the most commonly cited reason for discontinuing a prior therapy, identified by 57% of providers, while preference for a consistent treatment schedule was the ...
Former NASCAR driver Darrell Waltrip recently announced a diagnosis of frontotemporal dementia (FTD). Waltrip, a 3-time ...
Tasimelteon advanced sleep onset by 42.5 minutes versus 5.4 minutes with placebo in DSWPD, meeting the primary endpoint with ...
Neurologists Robert Bermel, MD; Rebecca Cebull, CNP; and Marisa McGinley, DO, discuss where serum neurofilament light and GFAP fit into MS care today and why the field is still waiting on a biomarker ...
Congressional passage would extend ACT for ALS programs and associated research grants through FY2031, sustaining federal ...
Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results